2024
PERFORMANCE OF THE PROMISE MINIMAL RISK SCORE IN STABLE ANGINA PATIENTS IN THE PROSPECTIVE RANDOMIZED TRIAL OF THE OPTIMAL EVALUATION OF CARDIAC SYMPTOMS AND REVASCULARIZATION (PRECISE) TRIAL
Kelsey M, Nanna M, Vemulapalli S, Yow E, Chiswell K, Ng N, Mark D, Pier K, Huey W, Mullen S, Rogers C, Fordyce C, Udelson J, Douglas P. PERFORMANCE OF THE PROMISE MINIMAL RISK SCORE IN STABLE ANGINA PATIENTS IN THE PROSPECTIVE RANDOMIZED TRIAL OF THE OPTIMAL EVALUATION OF CARDIAC SYMPTOMS AND REVASCULARIZATION (PRECISE) TRIAL. Journal Of The American College Of Cardiology 2024, 83: 1330. DOI: 10.1016/s0735-1097(24)03320-5.Peer-Reviewed Original Research
2021
The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial
Nanna MG, Vemulapalli S, Fordyce CB, Mark DB, Patel MR, Al-Khalidi HR, Kelsey M, Martinez B, Yow E, Mullen S, Stone GW, Ben-Yehuda O, Udelson JE, Rogers C, Douglas PS. The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. American Heart Journal 2021, 245: 136-148. PMID: 34953768, PMCID: PMC8979644, DOI: 10.1016/j.ahj.2021.12.004.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseStable chest painChest painDiagnostic strategiesUsual careCardiac symptomsMajor adverse cardiac eventsNon-acute chest painObstructive coronary artery diseaseInitial diagnostic strategyInvasive cardiac catheterizationUse of CCTAUsual care strategyAdverse cardiac eventsProspective randomized trialsClinical care teamFractional flow reserveQuality of lifeHealth care costsOptimal evaluationPrimary endpointRevascularization TrialSecondary endpointsCardiac eventsArtery disease